Formation of adriamycin-DNA adductsin vitro

Dithiothreitol, a New Protective Reagent for SH Groups^*

1964 • 1,933 citations

Overview of enzyme systems involved in bioreduction of drugs and in redox cycling

1986 • 392 citations

Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex

1982 • 238 citations

DNA Topoisomerases as Anticancer Drug Targets

1990 • 195 citations

Methidiumpropyl-EDTA-Fe(II) and DNase I footprinting report different small molecule binding site sizes on DNA

1983 • 175 citations

The molecular pharmacology of doxorubicin in vivo

1991 • 151 citations

Reaction of DNA with chemically or enzymatically activated mitomycin C: isolation and structure of the major covalent adduct.

1986 • 144 citations

Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells.

1991 • 109 citations

Free radicals in anticancer drug pharmacology

1989 • 106 citations

Enzymatic activation and binding of adriamycin to nuclear DNA.

1984 • 94 citations

Induction of stable transcriptional blockage sites by Adriamycin: GpC specificity of apparent Adriamycin-DNA adducts and dependence on iron(III) ions

1990 • 84 citations

One-electron reduction of adriamycin: Properties of the semiquinone

1983 • 77 citations

Xanthine oxidase catalyzed reductive cleavage of anthracycline antibiotics and free radical formation.

1980 • 74 citations

DNA topoisomerase-trapping antitumour drugs

1992 • 69 citations

Solution chemistry studies of adriamycin-iron complexes present in vivo

1980 • 68 citations

Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors?

1991 • 56 citations

Enhancement of doxorubicin toxicity following activation by NADPH cytochrome P450 reductase

1992 • 50 citations

Role of iron in adriamycin biochemistry.

1986 • 50 citations

Comparison of dna cleavage induced by etoposide and doxorubicin in two human small‐cell lung cancer lines with different sensitivities to topoisomerase ii inhibitors

1990 • 49 citations

DNA sequence‐specific adducts of adriamycin and mitomycin C

1989 • 47 citations

Role of quinone-iron(III) interaction in NADPH-dependent enzymic generation of hydroxyl radicals

1992 • 46 citations

The consequences of doxorubicin quinone reduction in vivo in tumour tissue

1992 • 45 citations

Reactions of Adriamycin with haemoglobin. Superoxide dismutase indirectly inhibits reactions of the Adriamycin semiquinone

1982 • 43 citations

Role of Daunosamine and Hydroxyacetyl Side Chain in Reaction With Iron and Lipid Peroxidation by Anthracyclines

1988 • 43 citations

Anthracycline antibiotic reduction by spinach ferredoxin-NADP+ reductase and ferredoxin

1985 • 40 citations

Binding of [14C]-adriamycin to cellular macromolecules in vivo

1980 • 40 citations

Iron(III) binding in DNA solutions: Complex formation and catalytic activity in the oxidation of hydrazine derivatives

1991 • 36 citations

Determination of covalent binding to intact DNA, RNA, and oligonucleotides by intercalating anticancer drugs using high-performance liquid chromatography. Studies with doxorubicin and NADPH cytochrome P-450 reductase

1991 • 33 citations

Reappraisal of the association between adriamycin and iron.

1988 • 31 citations

Elucidation of the DNA sequence preferences of daunomycin.

1988 • 21 citations

Circumvention of resistance by doxorubicin, but not by idarubicin, in a human leukemia cell line containing an intercalator-resistant form of topoisomerase II: evidence for a non-topoisomerase II-mediated mechanism of doxorubicin cytotoxicity

1993 • 21 citations

Binding of transferrin‐iron by adriamycin at acidic pH

1986 • 21 citations

High-affinity iron binding by xanthine oxidase

1986 • 8 citations

Anthracyclines.

1992 • 2 citations